Cbd oil vs medical marijuana for depression

Study Finds Medical Marijuana May Help Treat Depression And Anxiety And Improve Sleep

A recent study of people diagnosed with clinical depression has found that those using medical marijuana had lower depression scores than those who were not cannabis users. Researchers also determined that study participants who began using medicinal cannabis in a follow-up period saw a reduction in both depression and anxiety symptoms.

Depression affects more than 300 million people globally, according to statistics from the Hope for Depression Research Foundation, making it one of the most debilitating medical conditions in the world. In the United States, generalized anxiety disorder affects up to 4% of the population, or as many as 9 million people nationwide.

“Anxiety and depressive disorders are highly prevalent,” Erin L. Martin, lead author of the study and a Ph.D. candidate at the Medical University of South Carolina, told PsyPost. “Traditional antidepressants may effectively treat these disorders in a lot of people, but they do not work for everyone and can have unpleasant side effects.”

Many people with mental health challenges are choosing medical marijuana over antidepressants and . [+] other pharmaceutical drugs.

As an alternative to commonly prescribed pharmaceuticals, many people with anxiety and depression turn to cannabis products containing tetrahydrocannabinol (THC) or cannabidiol (CBD), or a combination of the two cannabinoids. However, scientific evidence of the efficacy of cannabis products to treat symptoms of anxiety and depression have not been conclusive.

“We conducted this study to determine if people that used medicinal cannabis products to treat symptoms of anxiety and depression reported improvement in these symptoms, as well as in other important areas like sleep and quality of life, relative to people that did not use medicinal cannabis,” Martin explained.

Best Travel Insurance Companies

Best Covid-19 Travel Insurance Plans

To conduct the study, which was published recently in the journal Frontiers in Psychiatry, researchers recruited a group of participants who reported having depression, anxiety, or both. Of them, 368 were medical cannabis users, while 170 said that they did not use cannabis medicinally but were considering doing so.

See also  Cbd oil for ibs pain

During a baseline assessment, participants answered questions about their cannabis use and completed assessments that gauge anxiety, depression, recent pain, quality of life, and sleep quality. Participants were invited to complete follow-up assessments every three months over a period of three years. Those enrolled in the study completed an average of two assessments during the course of research.

Among the study participants, 34% reported having anxiety, 15% reported having depression and 51% said they had both conditions. More than two-third (69%) also said they chronic pain disorder. CBD-dominant cannabis products were the most popular, with 82% of study participants reporting their use. Nearly a quarter (23%) reported using THC products, 7% said they used products with an equal balance of THC and CBD, and 5% used cannabis products with a minor cannabinoid.

Cannabis Users Had Lower Levels Of Depression

The participants who used cannabis at baseline, particularly CBD-rich products, reported lower levels of depression than nonusers. Those who used cannabis also reported higher quality of life, better sleep in the past month, less pain in the past month and were more likely to exhibit symptoms of depression that did not rise to the level of clinical concern.

Anxiety levels did not differ between cannabis users and nonusers at the onset of the study. Participants who were not cannabis users at the beginning of the research but began using cannabis medicinally during the follow-up period showed reductions in both depression and anxiety, as well as improvements in quality of life.

“Medicinal cannabis products, especially products high in CBD, may help to treat symptoms of depression, improve sleep, and increase quality of life,” said Martin. “There is also some evidence that medicinal cannabis may alleviate symptoms of anxiety, particularly if administered over an extended period of time, but this is less clear from our results and warrants further study.”

See also  Is cbd oil for dogs the same as for humans

More Study Needed

Authors of the small study reported several limitations of the research, including a reliance on self-reporting and other factors, and recommended further investigation to explore efficacy and dosage.

“This is an observational study in a convenience sample, so it is possible that the results we observed could be partially attributable to a placebo effect or to people being more likely to complete the study if they found medicinal cannabis products effectively treated their symptoms,” Martin explained.

“Randomized, placebo-controlled trials on the antidepressant and anxiolytic effects of medicinal cannabis are needed,” she added. “Furthermore, it is still unknown how people should be dosing medicinal cannabis products in order to achieve the best effect (How much? How long? What cannabinoid content?) This should also be explored in future research.”

The study, “Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial,” was published by the journal Frontiers in Psychiatry last month.

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa

Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.

Similar articles

Gomes FV, Resstel LB, Guimarães FS. Gomes FV, et al. Psychopharmacology (Berl). 2011 Feb;213(2-3):465-73. doi: 10.1007/s00213-010-2036-z. Epub 2010 Oct 14. Psychopharmacology (Berl). 2011. PMID: 20945065

See also  Cbd oil for sale in newport ar

Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Schier AR, et al. Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10. doi: 10.1590/s1516-44462012000500008. Braz J Psychiatry. 2012. PMID: 22729452 Review. English, Portuguese.

Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SR. Zanelati TV, et al. Br J Pharmacol. 2010 Jan;159(1):122-8. doi: 10.1111/j.1476-5381.2009.00521.x. Epub 2009 Dec 4. Br J Pharmacol. 2010. PMID: 20002102 Free PMC article.

Chaves YC, Genaro K, Crippa JA, da Cunha JM, Zanoveli JM. Chaves YC, et al. Metab Brain Dis. 2021 Apr;36(4):639-652. doi: 10.1007/s11011-020-00667-3. Epub 2021 Jan 19. Metab Brain Dis. 2021. PMID: 33464458

Campos AC, Guimarães FS. Campos AC, et al. Psychopharmacology (Berl). 2008 Aug;199(2):223-30. doi: 10.1007/s00213-008-1168-x. Epub 2008 May 1. Psychopharmacology (Berl). 2008. PMID: 18446323

Cited by 54 articles

Tran DD, Fitzke RE, Wang J, Davis JP, Pedersen ER. Tran DD, et al. Psychol Rep. 2022 Mar 24:332941221080413. doi: 10.1177/00332941221080413. Online ahead of print. Psychol Rep. 2022. PMID: 35324356 Free PMC article.

Maguire RF, Wilkinson DJ, England TJ, O’Sullivan SE. Maguire RF, et al. Med Cannabis Cannabinoids. 2021 Jul 29;4(2):86-96. doi: 10.1159/000517120. eCollection 2021 Winter. Med Cannabis Cannabinoids. 2021. PMID: 35224428 Free PMC article.

Hen-Shoval D, Weller A, Weizman A, Shoval G. Hen-Shoval D, et al. Int J Environ Res Public Health. 2022 Jan 4;19(1):523. doi: 10.3390/ijerph19010523. Int J Environ Res Public Health. 2022. PMID: 35010782 Free PMC article. Review.

Gallego-Landin I, García-Baos A, Castro-Zavala A, Valverde O. Gallego-Landin I, et al. Front Pharmacol. 2021 Dec 6;12:762738. doi: 10.3389/fphar.2021.762738. eCollection 2021. Front Pharmacol. 2021. PMID: 34938182 Free PMC article. Review.

Mirzamohammad E, Alirezalu A, Alirezalu K, Norozi A, Ansari A. Mirzamohammad E, et al. Food Sci Nutr. 2021 Oct 25;9(12):6873-6881. doi: 10.1002/fsn3.2643. eCollection 2021 Dec. Food Sci Nutr. 2021. PMID: 34925815 Free PMC article.